[{"address1": "3650 Gilmore Way", "address2": "Suite 200", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 251, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 47, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1066715, "exercisedValue": 2366401, "unexercisedValue": 29581198}, {"maxAge": 1, "name": "Ms. Sherry  Aulin C.A., CPA", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 664799, "exercisedValue": 0, "unexercisedValue": 4300444}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 62, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.", "age": 44, "title": "Chief Commercial Officer", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 621120, "exercisedValue": 0, "unexercisedValue": 4922073}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719820, "exercisedValue": 0, "unexercisedValue": 3669313}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 55, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 200510, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McCloskey B.A.", "age": 63, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 62, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sheila M. Grant M.B.A., M.Sc., MBA", "title": "Executive Vice President of R&D Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 39.45, "open": 39.02, "dayLow": 38.95, "dayHigh": 40.34, "regularMarketPreviousClose": 39.45, "regularMarketOpen": 39.02, "regularMarketDayLow": 38.95, "regularMarketDayHigh": 40.34, "beta": 1.251, "forwardPE": -11.448091, "volume": 418485, "regularMarketVolume": 418485, "averageVolume": 369459, "averageVolume10days": 354960, "averageDailyVolume10Day": 354960, "bid": 39.93, "ask": 40.18, "bidSize": 100, "askSize": 100, "marketCap": 3053395968, "fiftyTwoWeekLow": 35.53, "fiftyTwoWeekHigh": 50.99, "fiftyDayAverage": 41.8624, "twoHundredDayAverage": 41.00585, "currency": "USD", "enterpriseValue": 2468334336, "floatShares": 69992765, "sharesOutstanding": 76239600, "sharesShort": 2888180, "sharesShortPriorMonth": 3301156, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0381, "heldPercentInsiders": 0.0037599998, "heldPercentInstitutions": 1.01181, "shortRatio": 7.75, "shortPercentOfFloat": 0.038399998, "impliedSharesOutstanding": 83042200, "bookValue": 12.311, "priceToBook": 3.2531881, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -199060000, "trailingEps": -2.81, "forwardEps": -3.56, "enterpriseToEbitda": -10.563, "52WeekChange": -0.026731491, "SandP52WeekChange": 0.2764505, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "XENE", "underlyingSymbol": "XENE", "shortName": "Xenon Pharmaceuticals Inc.", "longName": "Xenon Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1415197800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "64704bd1-0bc0-37c9-bd0d-60b8ec0eaa04", "messageBoardId": "finmb_565718", "gmtOffSetMilliseconds": -18000000, "currentPrice": 40.05, "targetHighPrice": 65.0, "targetLowPrice": 46.0, "targetMeanPrice": 57.1875, "targetMedianPrice": 59.0, "recommendationMean": 1.35294, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 16, "totalCash": 721534976, "totalCashPerShare": 9.523, "ebitda": -233680992, "totalDebt": 10033000, "quickRatio": 23.091, "currentRatio": 23.273, "debtToEquity": 1.189, "returnOnAssets": -0.18924, "returnOnEquity": -0.26709998, "freeCashflow": -104091504, "operatingCashflow": -153552000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]